Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine Efficacy and Safety in Acute Exacerbation of Schizophrenia
NCT00156104Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jul 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (4 arms), sponsored by Organon & Co. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Jul 2005; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00156104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156104.